Moral Investing's  Instablog

Moral Investing
Send Message
Private investor.
  • Deeper Research: Eisai Advertising Key Role Position 7 comments
    Oct 2, 2013 10:13 AM | about stocks: ARNA

    The title of this instablog makes me feel like a recruiter, but to supplement an Osborne "unverified" rumor, I prefer to provide objective evidence to today's catch-up news from a published SA article.

    As it stands, first and foremost, Eisai is advertising a very critical and strategic position in its organization. There is no question in my thinking seeing the Americas scope of responsibility that Belviq falls under this person's responsibility. The full document can be searched on Eisai's website under careers, but I will provide some excerpts:

    Title Dir, Sales Training & Develop
    Department Name Sales Training
    Location/Territory Name Woodcliff Lake, NJ
    Job Description This role will provides strategic leadership to the sales training function for a portfolio of products focused in oncology and specialty markets to ensure maximum effectiveness of the sales force. The Director is responsible for the overall creation and delivery of tailored training and development solutions for an evolving market place.This includes oversight of content development and implementation/execution of all sales training programs. This extends to all of the Americas including Canada and Latin America.

    Furthermore, it is common knowledge that Eisai has been advertising additional sales positions. I may banter with Mr. Osborne, but in this case I think his "unverified" rumor has legs.

    However unlike some, I still maintain Arena is a STRONG BUY. Just remember, Eisai is on record of Belviq becoming a billion dollar block-buster in six years not only repeated in print in August 2013, but also going back in time. Despite any stock volatility, I remain VERY BULLISH on Arena Pharmaceuticals as the company also secured three very important patents just yesterday 1 October 2013:

    1 8546429 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
    The present invention relates to certain trisubstituted aryl and heteroaryl derivatives of Formula (NYSE:I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful...
    2 8546379 5HT2C receptor modulators
    The present invention relates to novel compounds of Formula (I): which act as 5HT2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment...
    3 8546378 5HT2C receptor modulator compositions and methods of use
    The present invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist. In addition, the invention relates to a composition comprising phentermine and a...

    I would be honored if you chose to FOLLOW ME as I will continue to write future unpublished reports since SA has chosen not to publish my articles.

    Disclosure: I am long ARNA.

    Additional disclosure: Unpublished instablog. Feel free to copy/paste and share with others.

    Stocks: ARNA
Back To Moral Investing's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (7)
Track new comments
  • PlainDealer
    , contributor
    Comments (91) | Send Message
    Good morning Moral Investing,


    Just the sort of news I want to see with my morning coffee! :)


    Thank you for taking the time to make this available to the retail investment community.


    2 Oct 2013, 10:25 AM Reply Like
  • Moral Investing
    , contributor
    Comments (66) | Send Message
    Author’s reply » Indeed, I'm reminded by you to remind each reader to pass this information along on other sites and chat boards. The more this information goes out, the better.
    2 Oct 2013, 10:28 AM Reply Like
  • Robert J. Yale
    , contributor
    Comments (301) | Send Message
    Solid info..thank you
    2 Oct 2013, 11:25 AM Reply Like
  • russim
    , contributor
    Comments (15) | Send Message
    Nice get to the point and no clutter article! Logical move by Eisai to add sales crew with new advertising at this stage.
    2 Oct 2013, 11:39 AM Reply Like
  • Abraxix
    , contributor
    Comments (362) | Send Message
    That's what I like...........granular information without the larding of excess verbiage or soft bashing (unlike some other writers we know). Keep up the good work!
    2 Oct 2013, 11:44 AM Reply Like
  • sts66
    , contributor
    Comments (3449) | Send Message
    Key words for that Sales Dir job:


    "This extends to all of the Americas including Canada and Latin America."


    Hmmm....where are the next targets for expansion of Belviq sales, eh?
    2 Oct 2013, 12:17 PM Reply Like
  • m_yossi
    , contributor
    Comments (277) | Send Message



    Cardiac Hypertrophy is a huge problem.
    If they have a treatment for Diastolic Dysfunction (even if it will help only 30%) then it’s great imo!


    They can start from phase IIb…
    12 Oct 2013, 08:26 AM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.